Company: AZN
Filing Date: 2025-10-07
Form Type: 6-K
Source: 0001654954-25-011529
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-10-07
Form: 6-K
Chunk 7
---
 population-representative studies with 104 million participants. Lancet . 2021 Sep 11;398(10304):957-980. doi: 10.1016/S0140-6736(21)01330-1.

23. Cannavo A, et al. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology . Oxid Med Cell Longev. 2018;2018:1204598. Accessed September 2025.

24. Inoue K, et al. Serum aldosterone concentration, blood pressure, and coronary artery calcium: The multi-ethnic study of atherosclerosis . Hypertension. 2020;76(1):113-120. Accessed September 2025.

25. van Oort S, et al. Association of cardiovascular risk factors and lifestyle behaviors with hypertension: a mendelian randomization study . Hypertension. 2020;76(6):1971-1979.

26. Freeman MW, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension . N Engl J Med. 2023;388(5):395-405. Accessed September 2025.

27. AstraZeneca 2023. Acquisition of CinCor Pharma complete. https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset.html. Accessed September 2025.

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date:07 October 2025

| By: /s/           
 Matthew Bowden    |
| Name:             
 Matthew Bowden    |
| Title:            
 Company Secretary |